Short answer · Medically reviewed summary · Last updated: 2026-05-08
The primary ICD-10 code for malignant neoplasm of the ovary is C56, while the ICD-9-CM classification for ovarian cancer is categorized under 183.0. These codes are essential for clinical documentation, insurance billing, and tracking the global prevalence of ovarian cancer within healthcare systems. Why are ICD codes important for ovarian cancer patients? ICD (International Classification of Diseases) codes provide a standardized language for healthcare providers to report ovarian cancer diagnoses.
The primary ICD-10 code for malignant neoplasm of the ovary is C56, while the ICD-9-CM classification for ovarian cancer is categorized under 183.0. These codes are essential for clinical documentation, insurance billing, and tracking the global prevalence of ovarian cancer within healthcare systems.
ICD (International Classification of Diseases) codes provide a standardized language for healthcare providers to report ovarian cancer diagnoses. These codes ensure that treatment plans, surgical interventions, and chemotherapy protocols are accurately documented in medical records. For the 60 members of the DiseaseMaps community currently navigating ovarian cancer, understanding these codes can assist in communicating effectively with insurance providers and coordinating multidisciplinary oncology care.
While C56 is the primary designation, medical coders often use sub-codes to specify the exact location and histology of the tumor. Because ovarian cancer is a complex disease with various subtypes—such as epithelial, germ cell, or stromal tumors—the classification system allows for granular detail to improve research outcomes. Key coding considerations include:
The diagnostic criteria for ovarian cancer remain consistent globally, though coding practices may vary slightly by country. Clinicians rely on imaging (CT, MRI) and histopathological review to confirm a diagnosis of ovarian cancer, which is then translated into these codes. Accurate coding is vital for medical researchers who analyze data to improve survival rates and develop new therapies for those living with ovarian cancer.
Medical disclaimer: This information is for educational purposes only and does not constitute formal medical advice; always consult your primary oncology team for clinical decisions.